精巣がん治療薬市場レポート：がんタイプ、薬剤タイプ、流通チャネル、地域別、2024年～2032年

精巣がん治療薬の世界市場規模は2023年に6億8,660万米ドルに達しました。今後、IMARC Groupは、市場は2032年までに10億2,820万米ドルに達し、2024年から2032年の間に4.45％の成長率（CAGR）を示すと予測しています。精巣がんの罹患率の上昇、がん治療のための財政援助を提供する有利な政府政策の実施、消費者の支出能力の上昇、ライフスタイルの変化などが市場を牽引する主な要因です。

精巣がんは、テストステロンと精子の生産を担う男性の生殖器官である睾丸に発症する疾患です。精巣の腫れ、痛みや不快感、下腹部の重苦しさや痛みなどは、精巣がんの一般的な症状の一部です。精巣がんは、病歴評価、身体診察、超音波画像検査、血液検査などを組み合わせて診断されます。精巣がん治療薬は、精巣がんの治療に使用される薬物療法です。シスプラチン、エトポシド、イホスファミド、ビンブラスチン、ブレオマイシンなどが一般的な薬剤です。これらの薬剤はがん細胞を標的として死滅させ、腫瘍を縮小させ、体の他の部分へのがんの転移を防ぐ。

世界の精巣がん治療薬の市場動向：

遺伝的素因、特定の環境要因への曝露、ライフスタイルの変化などによる精巣がんの罹患率の上昇は、市場成長を促進する重要な要因のひとつです。これに伴い、精巣がんに対する意識の高まりと早期発見の重要性が診断率の上昇につながっており、これが市場の成長を後押ししています。これとは別に、腫瘍学、特に精巣がんにおける研究開発（R&D）の継続的な取り組みにより、新薬や治療オプションが発見され、市場成長に大きな後押しとなっています。さらに、精巣がんの早期発見と正確な診断を可能にする画像診断技術や腫瘍マーカーなどの高度な診断ツールが容易に利用できるようになったことも、市場の成長に寄与しています。さらに、意識を高め、ヘルスケア・インフラを改善し、がん治療のための財政援助を提供するためのさまざまな政府イニシアチブの実施は、市場成長にプラスの影響を与えています。その他にも、急速な技術進歩、消費者の支出能力の上昇、革新的な精巣がん治療薬を開発するための製薬会社、研究機関、ヘルスケア機関の協力関係の増加、医療業界の著しい成長などが、市場に有益な成長機会をもたらしています。

本レポートで扱う主な質問

• 世界の精巣がん治療薬の市場における促進要因、抑制要因、および機会は何か各駆動要因、抑制要因、および機会が世界の精巣がん治療薬の市場に与える影響は何か主要な地域市場は何か最も魅力的な精巣がん治療薬の市場を代表する国はどこかがんタイプに基づく市場内訳は何か？精巣がん治療薬の市場において最も魅力的ながんタイプはどれか？薬剤タイプに基づく市場の内訳は何か？ 精巣がん治療薬の市場において最も魅力的な薬剤タイプはどれか？流通チャネルに基づく市場の内訳は何か？世界の精巣がん治療薬の市場における競合構造は？世界の精巣がん治療薬の市場における主要プレイヤー／企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 世界の精巣がん治療薬市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：がんタイプ別

• セミノーマ
  • 市場動向
  • 主要セグメント
    • クラシック（典型的）
    • 精母細胞
  • 市場予測
• 非セミノーマ
  • 市場動向
  • 市場動向
    • 胎児性がん
    • 卵黄嚢がん
    • 絨毛がん
    • 奇形腫
    • その他
  • 市場予測

第7章 市場内訳：薬剤タイプ別

• シスプラチン
  • 市場動向
  • 市場予測
• エトポシド
  • 市場動向
  • 市場予測
• イホスファミド
  • 市場動向
  • 市場予測
• ビンブラスチン
  • 市場動向
  • 市場予測
• ブレオマイシン
  • 市場動向
  • 市場予測
• その他
  • 市場動向
  • 市場予測

第8章 市場内訳：流通チャネル別

• 病院薬局
  • 市場動向
  • 市場予測
• 小売薬局
  • 市場動向
  • 市場予測
• オンライン薬局
  • 市場動向
  • 市場予測
• その他
  • 市場動向
  • 市場予測

第9章 市場内訳：地域別

• 北米
  • 米国
  • カナダ
• アジア太平洋地域
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
• 中東・アフリカ
  • 市場動向
  • 市場内訳：国別
  • 市場予測

第10章 促進要因・抑制要因・機会

• 概要
• 促進要因
• 抑制要因
• 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第13章 価格分析

第14章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Bristol-Myers Squibb Company
  • Fresenius SE & Co. KGaA
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

List of Figures

• Figure 1: Global: Testicular Cancer Drugs Market: Major Drivers and Challenges
• Figure 2: Global: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018-2023
• Figure 3: Global: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 4: Global: Testicular Cancer Drugs Market: Breakup by Type of Cancer (in %), 2023
• Figure 5: Global: Testicular Cancer Drugs Market: Breakup by Drug Type (in %), 2023
• Figure 6: Global: Testicular Cancer Drugs Market: Breakup by Distribution Channel (in %), 2023
• Figure 7: Global: Testicular Cancer Drugs Market: Breakup by Region (in %), 2023
• Figure 8: Global: Testicular Cancer Drugs (Seminoma) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 9: Global: Testicular Cancer Drugs (Seminoma) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 10: Global: Testicular Cancer Drugs (Non-Seminoma) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 11: Global: Testicular Cancer Drugs (Non-Seminoma) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 12: Global: Testicular Cancer Drugs (Cisplatin) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 13: Global: Testicular Cancer Drugs (Cisplatin) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 14: Global: Testicular Cancer Drugs (Etoposide) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 15: Global: Testicular Cancer Drugs (Etoposide) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 16: Global: Testicular Cancer Drugs (Ifosfamide) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 17: Global: Testicular Cancer Drugs (Ifosfamide) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 18: Global: Testicular Cancer Drugs (Vinblastine) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 19: Global: Testicular Cancer Drugs (Vinblastine) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 20: Global: Testicular Cancer Drugs (Bleomycin) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 21: Global: Testicular Cancer Drugs (Bleomycin) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 22: Global: Testicular Cancer Drugs (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 23: Global: Testicular Cancer Drugs (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 24: Global: Testicular Cancer Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 25: Global: Testicular Cancer Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 26: Global: Testicular Cancer Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 27: Global: Testicular Cancer Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 28: Global: Testicular Cancer Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 29: Global: Testicular Cancer Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 30: Global: Testicular Cancer Drugs (Others) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 31: Global: Testicular Cancer Drugs (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 32: North America: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 33: North America: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 34: United States: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 35: United States: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 36: Canada: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 37: Canada: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 38: Asia-Pacific: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 39: Asia-Pacific: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 40: China: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 41: China: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 42: Japan: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 43: Japan: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 44: India: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 45: India: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 46: South Korea: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 47: South Korea: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 48: Australia: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 49: Australia: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 50: Indonesia: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 51: Indonesia: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 52: Others: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 53: Others: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 54: Europe: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 55: Europe: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 56: Germany: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 57: Germany: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 58: France: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 59: France: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 60: United Kingdom: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 61: United Kingdom: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 62: Italy: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 63: Italy: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 64: Spain: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 65: Spain: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 66: Russia: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 67: Russia: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 68: Others: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 69: Others: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 70: Latin America: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 71: Latin America: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 72: Brazil: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 73: Brazil: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 74: Mexico: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 75: Mexico: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 76: Others: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 77: Others: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 78: Middle East and Africa: Testicular Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 79: Middle East and Africa: Testicular Cancer Drugs Market: Breakup by Country (in %), 2023
• Figure 80: Middle East and Africa: Testicular Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 81: Global: Testicular Cancer Drugs Industry: Drivers, Restraints, and Opportunities
• Figure 82: Global: Testicular Cancer Drugs Industry: Value Chain Analysis
• Figure 83: Global: Testicular Cancer Drugs Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Testicular Cancer Drugs Market: Key Industry Highlights, 2023 & 2032
• Table 2: Global: Testicular Cancer Drugs Market Forecast: Breakup by Type of Cancer (in Million US$), 2024-2032
• Table 3: Global: Testicular Cancer Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
• Table 4: Global: Testicular Cancer Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
• Table 5: Global: Testicular Cancer Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
• Table 6: Global: Testicular Cancer Drugs Market: Competitive Structure
• Table 7: Global: Testicular Cancer Drugs Market: Key Players

The global testicular cancer drugs market size reached US$ 686.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,028.2 Million by 2032, exhibiting a growth rate (CAGR) of 4.45% during 2024-2032. The rising incidence of testicular cancer, the implementation of favorable government policies to provide financial aid for cancer treatment, the rising expenditure capacities of consumers, and changing lifestyles represent some of the key factors driving the market.

Testicular cancer is a disease that develops in the testicles, which is the male reproductive organ responsible for producing testosterone and sperm. Swelling in the testicle, pain or discomfort, and heaviness or ache in the lower abdomen are some of the common symptoms of testicular cancer. It is diagnosed through a combination of medical history evaluation, physical examination, ultrasound imaging, and blood tests. Testicular cancer drugs are medications and therapies used in treating testicular cancer. Cisplatin, etoposide, ifosfamide, vinblastine, bleomycin are some of the common drugs. They target and kill cancer cells, shrinking tumors and preventing the spread of cancer to other parts of the body.

Global Testicular Cancer Drugs Market Trends:

The rising incidence of testicular cancer due to genetic predisposition, exposure to certain environmental factors, and changing lifestyles is one of the key factors propelling the market growth. In line with this, the growing awareness about testicular cancer and the importance of early detection has led to higher diagnosis rates, which, in turn, is favoring the market growth. Apart from this, ongoing research and development (R&D) efforts in oncology, specifically in testicular cancer, have led to the discovery of new drugs and treatment options, which is providing a considerable boost to the market growth. Moreover, the easy availability of advanced diagnostic tools, such as imaging techniques and tumor markers, that enable early detection and accurate diagnosis of testicular cancer is contributing to the market growth. Furthermore, the implementation of various government initiatives to raise awareness, improve healthcare infrastructure, and provide financial aid for cancer treatment is positively influencing the market growth. Other factors, including rapid technological advancements, rising expenditure capacities of consumers, increasing collaborations between pharmaceutical companies, research institutes, and healthcare organizations to develop innovative testicular cancer drugs, and significant growth in the medical industry, are presenting remunerative growth opportunities for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global testicular cancer drugs market, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on the type of cancer, drug type, and distribution channel.

Type of Cancer Insights:

Seminoma

Classical (Typical)

Spermatocytic

Non-Seminoma

Embryonal Carcinoma

Yolk Sac Carcinoma

Choriocarcinoma

Teratoma

Others

The report has provided a detailed breakup and analysis of the testicular cancer drugs market based on the type of cancer. This includes seminoma (classical (Typical) and spermatocytic) and non-seminoma (embryonal carcinoma, yolk sac carcinoma, choriocarcinoma, teratoma, and others). According to the report, seminoma represented the largest segment.

Drug Type Insights:

Cisplatin

Etoposide

Ifosfamide

Vinblastine

Bleomycin

Others

The report has provided a detailed breakup and analysis of the testicular cancer drugs market based on the drug type. This includes cisplatin, etoposide, ifosfamide, vinblastine, bleomycin, and others.

Distribution Channel Insights:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

The report has provided a detailed breakup and analysis of the testicular cancer drugs market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, online pharmacies, and others. According to the report, hospital pharmacies represented the largest segment.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for testicular cancer drugs. Some of the factors driving the North America testicular cancer drugs market included rapid technological advancements, extensive research and development (R&D) activities, and rising incidences of testicular cancer.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the testicular cancer drugs market. Detailed profiles of all major companies have been provided. Some of the companies covered include Bristol-Myers Squibb Company, Fresenius SE & Co. KGaA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

• How has the global testicular cancer drugs market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global testicular cancer drugs market?
• What is the impact of each driver, restraint, and opportunity on the global testicular cancer drugs market?
• What are the key regional markets?
• Which countries represent the most attractive testicular cancer drugs market?
• What is the breakup of the market based on the type of cancer?
• Which is the most attractive type of cancer in the testicular cancer drugs market?
• What is the breakup of the market based on the drug type?
• Which is the most attractive drug type in the testicular cancer drugs market?
• What is the breakup of the market based on the distribution channel?
• Which is the most attractive distribution channel in the testicular cancer drugs market?
• What is the competitive structure of the global testicular cancer drugs market?
• Who are the key players/companies in the global testicular cancer drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Testicular Cancer Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type of Cancer

• 6.1 Seminoma
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Classical (Typical)
    • 6.1.2.2 Spermatocytic
  • 6.1.3 Market Forecast
• 6.2 Non-Seminoma
  • 6.2.1 Market Trends
  • 6.2.2 Market Trends
    • 6.2.2.1 Embryonal Carcinoma
    • 6.2.2.2 Yolk Sac Carcinoma
    • 6.2.2.3 Choriocarcinoma
    • 6.2.2.4 Teratoma
    • 6.2.2.5 Others
  • 6.2.3 Market Forecast

7 Market Breakup by Drug Type

• 7.1 Cisplatin
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Etoposide
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Ifosfamide
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Vinblastine
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Bleomycin
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Hospital Pharmacies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Retail Pharmacies
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Online Pharmacies
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

• 10.1 Overview
• 10.2 Drivers
• 10.3 Restraints
• 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Bristol-Myers Squibb Company
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Fresenius SE & Co. KGaA
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Pfizer Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Teva Pharmaceutical Industries Ltd.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.